The FDA has approved an HPV DNA test to be used as a primary screening method for cervical cancer in women 25 and older. The test can also give insight into future risk of cervical cancer.
An FDA panel has recommended that a DNA test that screens for HPV in women can replace the standard Pap smear as a first-line primary cervical cancer screening test.
A new study has demonstrated that a therapeutic vaccine against HPV can stimulate an immune response and regression of high-grade cervical dysplasia, a precursor to cervical cancer in women with an HPV infection.
Biennial visual inspection with acetic acid (vinegar) screening by trained public health workers significantly reduced cervical cancer mortality in a large cluster-randomized controlled trial conducted among thousands of women from poor neighborhoods in Mumbai, India.
Results from the phase III GOG 240 trial, presented at ASCO, showed the addition of bevacizumab (Avastin) to standard chemotherapy improved overall survival by nearly 4 months in women with advanced or relapsed cervical cancer.
In this interview we discuss HPV-associated cancers, which are on the rise, and the low vaccination coverage for HPV with Edgar Simard, PhD, MPH, senior epidemiologist of surveillance research, who studies the impact of prevention and screening on cancer incidence at the American Cancer Society.
There has been a decline in overall cancer screening among the US population. Only colorectal cancer screening rates met current screening goals. Cancer survivors specifically met current national screening goals with the exception of cervical cancer screening.
A new study finds that baseline testing for HPV can better predict long-term negative cervical cancer outcomes compared to a Pap smear.
The European Society of Gynaecological Oncology (ESGO) biennial meeting is taking place in Milan, Italy, and will run from September 11-14, 2011.
A study published in Lancet Oncology shows that an AS04-adjuvanted HPV 16 and HPV 18 vaccine developed by GlaxoSmithKline Biologicals can offer protection against anal cancer.